StockWatch
·

SUVEN LIFE SCIENCES LTD.

BSE: 530239

P/L Snapshot

Q2 FY27 · standalone

vs Q1 FY27·vs Q2 FY26
Revenue
7.93
-28.5%+68.9%
Expenditure
24.31
-10.6%+20.7%
Net Profit
-16.38
-1.6%-6.1%
OPM %
-100.00%

Shareholding

Pattern breakdown

P/L Trends

(in crores)

RevenueExpenditureNet Profit
-21.61-8.105.4118.9332.44Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Price Chart
Reports

Consolidated loss widens 38% YoY to ₹106.9 Cr as Phase 3 trial R&D spend climbs 43%

clinical stage biopharma · phase 3 trials · alzheimers trial

ResultsQ2 FY2705 Nov 20263 minPharma & Healthcare

Consolidated loss widens 148% YoY to ₹127.6 Cr as R&D spend surges on Phase 3 trials

clinical stage biopharma · phase 3 trial · r&d expense surge

ResultsQ1 FY2706 Aug 20263 minPharma & Healthcare
Latest
Quarterly Result5 Nov, 1:33 pm

Consolidated loss widens 38% YoY to ₹106.9 Cr as Phase 3 trial R&D spend climbs 43%

Suven Life Sciences posted a consolidated net loss of ₹106.94 Cr for Q2 FY27 (quarter ended 30 Sep 2026), widening 38.3% year-on-year from ₹77.31 Cr, with basic EPS at -₹3.77 versus -₹3.48 a year ago. There are no exceptional items on either side of the comparison, so this is a clean YoY read with no adjustment needed. Operating revenue remains practically nil at ₹1.20 Cr — up 30.4% YoY but down 66.4% QoQ — underscoring that this is a pre-revenue, clinical-stage biopharmaceutical; the ₹6.73 Cr of "other income" sitting in the P&L is investment/interest income on the company's cash and mutual-fund book, not operating income. Conventional margin ratios (NPM/OPM) aren't meaningful here given the near-absent revenue base; the real driver is R&D intensity. Consolidated R&D expense rose 42.7% YoY to ₹100.30 Cr (from ₹70.32 Cr) as the company ran parallel Phase 3 programs for masupirdine (Alzheimer's-related agitation) and samelisant (narcolepsy), pushing total consolidated expenses up 40.1% YoY to ₹114.88 Cr. Sequentially, expenses actually fell 17.2% QoQ and the loss narrowed 16.2% QoQ from ₹127.61 Cr in Q1 FY27 — a step-down in quarterly trial-cost intensity rather than a margin improvement, and since YoY is the primary lens here, the loss trajectory is still structurally widening as more trials run concurrently. Standalone and consolidated numbers diverge sharply enough that readers need the context: standalone net loss is just ₹16.38 Cr against the ₹106.94 Cr consolidated figure. The gap sits almost entirely in the US subsidiary, Suven Neurosciences Inc., which the auditors' limited-review report separately notes carried a standalone quarterly net loss of ₹90.53 Cr — that is where the bulk of Phase 3 clinical costs for the CNS pipeline is booked. No formal management guidance exists on record, and a search turned up no analyst/street consensus estimate for this specific quarter, so both vs-guidance and vs-street read as unknown rather than assumed. Management's own framing, per its news release, is clinical-progress-led rather than financial: SUVN-502 (masupirdine) completed Phase 3 patient enrollment for agitation in Alzheimer's dementia with topline data targeted for Q2 calendar-2027; SUVN-G3031 (samelisant) Phase 3 for narcolepsy is in progress; SUVN-911 (ropanicant) completed its US Phase 2B "with successful outcome" and targets global Phase 3 initiation in Q2 calendar-2027; and SUVN-D4010 (usmarapride) began a Phase 2 proof-of-concept study for cognitive dysfunction in October 2026. The quarter's financing action matters alongside the P&L: the board converted 1.857 crore warrants into equity during the quarter, bringing in ₹248.84 Cr and lifting standalone investments to ₹1,111.44 Cr; of the ₹857.64 Cr raised under the May-2025 preferential issue, ₹320.01 Cr remains unutilized as of 30 Sep 2026 to fund the ongoing Phase 3 programs. Going into Q3 FY27, the markers to watch are the masupirdine last-patient-last-visit (targeted Q1 calendar-2027, with topline data potentially Q2 calendar-2027) and whether the R&D run-rate keeps climbing against the remaining unutilized warrant proceeds.

5 Nov 2026, 01:33 pm

Corporate Events

Board MeetingSUVEN
2026
5Nov

Board Meeting

The meeting of the Board of Directors is scheduled to consid…

BSE Filing ↗
Board MeetingSUVEN
2026
25Aug

Board Meeting

The 37th Annual General Meeting (AGM) of shareholders of the…

BSE Filing ↗
Board MeetingSUVEN
2026
6Aug

Board Meeting

The meeting of the Board of Directors is scheduled to consid…

BSE Filing ↗
Board MeetingSUVEN
2026
8Jul

Board Meeting

The Board of Directors considered and approved the allotment…

BSE Filing ↗
Board MeetingSUVEN
2024
6May

Board Meeting

Consider and approve the Audited Financial Results of the Co…

BSE Filing ↗
Board MeetingSUVEN
2024
30Jan

Board Meeting

To consider and approve the Un-audited Financial Results (St…

BSE Filing ↗
Board MeetingSUVEN
2023
4Nov

Board Meeting

Consider and approve Un-audited Financial Results (Standalon…

BSE Filing ↗
Board MeetingSUVEN
2023
8Aug

Board Meeting

To consider and approve the Un-audited Financial Results (St…

BSE Filing ↗